# AI Life Sciences Investments LLC

> AI Life Sciences Investments LLC is a VC fund in New York backing Health Care and Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 5
- Last investment: Feb 2026
- Lead investor: 60%
- Last updated: Aug 2026

AI Life Sciences Investments LLC is a VC fund in New York focused on Health Care and Biotechnology. AI Life Sciences Investments is an affiliated company of Access Industries, specializing in investments across various stages of company growth, focusing on sectors like healthcare, SaaS, TMT, and technology. It actively seeks out promising opportunities to support innovation and growth in these industries.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 60% |
| Biotechnology | 2 | 40% |
| Pharmaceutical | 2 | 40% |
| Clinical Trials | 2 | 40% |
| mHealth | 1 | 20% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 20% |
| Series B | 1 | 20% |
| Series D | 1 | 20% |
| Post-IPO Debt | 1 | 20% |
| Private Equity | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 80% |
| Israel | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ILiAD Biotechnologies | ILiAD Biotechnologies (ILiAD) is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed a Phase 1 human clinical trial.ILiAD Biotechnologies is a registered Delaware companyfounded in 2012. | $115M | Series D | Feb 10, 2026 |  |
| Cortex | Cortex is creating an innovative, totally integrated, all-encompassing platform for assessing and treating AFib with precision, simplicity, and speed. The company has formed a proficient team comprising highly skilled and experienced engineers and clinical experts dedicated to introducing this innovative suite of technologies to the market. | $90M | Private Equity | Dec 07, 2023 |  |
| MyndYou | The MyndYou artificial intelligence (AI) based platform aids clinicians in providing personalized cognitive care for seniors living with or without cognitive decline. The MyndYou solution combines one-on-one remote interaction with a seamless monitoring app, analytic evaluation, and AI analysis to individualize care based on passively collecteddata from the client’s daily activities. The platform delivers actionable, objective insights in real-time to therapists during remote calls, guiding the nature and level of cognitive training. As cognitive related disease such as dementia and Alzheimer’s continues to grow at a rapid pace, MyndYou optimizes and scales the targeted delivery of cognitive care. | $4M | Series A | Apr 21, 2020 |  |
| Syndax Pharmaceuticals | Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias. | $30M | Post-IPO Debt | Jan 31, 2020 |  |
| SchoolCare | SchoolCare delivers free health technology for K-12 public schools to help school nurses deliver care and keep students safe. It is a digital health platform for the largest and most consistent health delivery system in the country. Their mission is to work with partners to provide a unified health record for every family. SchoolCare leveragespediatric health data and this country’s most successful public health organization, the K-12 school system, to improve outcomes and learn about clinical health data outside of the provider’s office. Traditional care coordination stops short of sending essential care instructions to School Nurses and thus increases the risk of stopped or inconsistent post-discharge care delivery. By closing the link in the pediatric care continuum, children stay healthy and get better faster. | $16M | Series B | Jan 17, 2018 |  |

5 of 5 investments shown.

## Co-investors
- AI Life Sciences Investments — VC Fund, 3 deals together
- [7wire Ventures](https://shizune.co/investors/profile/7wire-ventures) — VC Fund, 1 deal together
- [Access Industries](https://shizune.co/investors/profile/access-industries) — VC Fund, 1 deal together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 1 deal together
- [Amplifyher Ventures](https://shizune.co/investors/profile/amplifyher-ventures) — VC Fund, 1 deal together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does AI Life Sciences Investments LLC invest in?

AI Life Sciences Investments LLC invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did AI Life Sciences Investments LLC last invest?

The most recent investment recorded for AI Life Sciences Investments LLC closed in Feb 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co